Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Indolent non-Hodgkin lymphoma (iNHL) is a condition that is mostly incurable and frequently requires several lines of treatment, particularly when it becomes resistant to standard therapies. Duvelisib , which is the first oral dual inhibitor of phosphoinositide 3-kinase-d,-g, has received approval from the Food and Drug Administration for use in cases of relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL). It is also approved for RR follicular lymphoma (FL) after patients have undergone two or more previous systemi…